Edarbyclor is indicated for the treatment of hypertension (high blood pressure) to lower blood pressure. This combination medicine is commonly used to help with managing symptoms related to systemic imbalance (elevated pressure) in adults.

The primary therapeutic uses may include support in managing high blood pressure in situations where a single medication is not achieving control, its use as initial supportive management for severe essential hypertension, and its application in managing long-term cardiovascular risk factors. This combination is considered relevant in conditions characterized by periods of heightened symptoms where dual therapy supports achieving a significant pressure reduction.

A key therapeutic benefit provided by this medication is that lowering blood pressure supports the reduction of serious cardiovascular health consequences, such as strokes and myocardial infarctions.

“This medicine assists with maintaining functional stability by assisting in managing the long-term risk associated with chronic physiological strain on the vascular system.”

Quick Fact: Target: Elevated Blood Pressure

Eligibility Map: Who can and cannot use Edarbyclor

The official population eligibility for Edarbyclor (azilsartan medoxomil/chlorthalidone) is strictly defined by regulatory authorities and is generally restricted to adults (18 years and older) for the treatment of hypertension.

Populations for whom use is Contraindicated

Edarbyclor must not be used by the following groups, as formally stated in the regulatory labeling:

• Pregnant Women: The medication is contraindicated in the second and third trimesters, and must be discontinued immediately upon detection of pregnancy due to the risk of fetal injury and death.
• Patients with Anuria: Use is prohibited in patients who are unable to urinate.
• Diabetic Patients Taking Aliskiren: Co-administration with any aliskiren-containing product is an absolute contraindication.
• Hypersensitivity: Patients with a known allergy to the drug's components or to sulfonamide-derived medicines.

Restricted and Non-Recommended Use

• Pediatric Use: Safety and efficacy have not been established for children and adolescents under 18.
• Breastfeeding: Use is not recommended while breastfeeding.
• Severe Organ Impairment: Use is contraindicated or not recommended in cases of severe renal impairment (GFR less than 30 mL/min/1.73 m^2) or severe hepatic impairment.
• Volume Depletion: Patients who are volume- or salt-depleted must have this condition corrected before the medication is administered to avoid severe low blood pressure.

The regulatory profile for Edarbyclor documents several clinically significant interactions with other medicinal products and substances. A formal contraindication exists for co-administration with aliskiren-containing products in patients diagnosed with diabetes mellitus or those with renal impairment where the glomerular filtration rate ( GFR) is less than 60 mL/min. Combining Edarbyclor with other Angiotensin Receptor Blockers ( ARBs) or ACE inhibitors is not recommended due to the enhanced risk of hypotension, hyperkalemia, and changes in renal function from dual RAS blockade. The chlorthalidone component causes a pharmacokinetic interaction by reducing the renal clearance of lithium, thereby increasing the risk of lithium toxicity. Co-administration with Non-steroidal Anti-inflammatory Drugs ( NSAIDs) may attenuate the antihypertensive effect and increase the risk of renal function deterioration, a risk heightened in elderly or volume-depleted patients. Furthermore, concurrent use with potassium supplements, salt substitutes, or potassium-sparing diuretics may increase serum potassium levels. Certain bile acid resins may require a time separation of at least 2 hours before or 4 hours after the dose. The product may be taken with or without food, and the azilsartan component has no clinically significant interactions documented with major CYP metabolic pathways.

Edarbyclor contains two pharmacologically distinct agents: azilsartan and chlorthalidone.

Azilsartan, the active metabolite of the prodrug azilsartan medoxomil, acts as a selective, competitive antagonist at the angiotensin II type 1 ( AT1) receptor. This receptor antagonism occurs predominantly in tissues like vascular smooth muscle and the adrenal gland. The binding of azilsartan blocks the endogenous action of angiotensin II, a primary pressor agent of the Renin-Angiotensin-Aldosterone System (RAAS). Intracellularly, this blockade inhibits the AT1-mediated G-protein coupled signaling cascade that mediates vasoconstriction and stimulates aldosterone synthesis and release. The resulting systemic physiological consequence is the attenuation of peripheral resistance and a reduction in aldosterone-driven sodium and water retention.

Chlorthalidone, a thiazide-like diuretic, acts primarily on the renal distal convoluted tubule. Its molecular target is the Na^+- Cl^- cotransporter (NCC), which it inhibits. This inhibitory interaction decreases the reabsorption of sodium ( Na^+) and chloride ( Cl^-) from the tubule lumen. The downstream cascade involves an osmotic shift, resulting in enhanced urinary excretion of Na^+ and water. System-level physiological modulation includes a decrease in extracellular fluid volume and plasma volume, which, along with potential carbonic anhydrase inhibition, contributes to the overall systemic vascular modulation.

The fixed-dose combination medicine Edarbyclor is administered orally as a tablet for the long-term management of chronic high blood pressure.

The recommended starting dose for adults is the Azilsartan 40 mg/Chlorthalidone 12.5 mg strength, taken once daily. The dose is primarily based on the blood pressure response and may be increased, generally after 2 to 4 weeks of use, to the 40 mg/25 mg strength for maintenance. The overall dose should not exceed the maximum recommended daily limit of 40 mg/25 mg. The tablets may be taken with or without food.

Administration Principles

Population-Specific Use

It is established that pre-existing volume or salt depletion must be corrected before the medicine is initiated. For older adults (65 years and older), no initial dose adjustment is generally required. Furthermore, no modification to the starting dose is necessary for patients with mild to moderate hepatic or renal impairment (GFR ge 30 mL/min/1.73 m^2). The safety and effectiveness of Edarbyclor have not been established for use in the pediatric population.

Edarbyclor: Recent Clinical Evidence

Edarbyclor is a fixed-dose combination containing azilsartan medoxomil (an Angiotensin II Receptor Blocker, or ARB) and chlorthalidone (a thiazide-like diuretic). Clinical trials have primarily investigated its use in treating hypertension (high blood pressure) to evaluate its efficacy and safety profile.

Efficacy and Combination Studies

Research has explored the blood pressure-lowering effect of the combination compared to its individual components and other established antihypertensive agents. A factorial study design was often used to evaluate the contribution of each component to the overall effect. Findings from multiple randomized controlled trials have generally indicated that the combination product is associated with greater reductions in systolic and diastolic blood pressure compared to the monotherapy components alone.

Specific trials have also examined Edarbyclor against other common two-drug regimens, such as the combination of olmesartan plus hydrochlorothiazide. In these active-controlled studies, the azilsartan/chlorthalidone combination was observed to be associated with superior reductions in blood pressure, including 24-hour ambulatory blood pressure monitoring (ABPM) measurements.

Safety and Tolerability

The most commonly reported adverse events in clinical trials were generally mild to moderate in severity, including dizziness, fatigue, and headache. The combination product contains chlorthalidone, a diuretic known to affect serum electrolytes; therefore, periodic monitoring of electrolyte levels (e.g., potassium and sodium) is a standard safety measure used in clinical practice and trials. The safety profile observed in clinical studies for Edarbyclor has been generally comparable to other established combination therapies used for hypertension.

Key Studies & References Efficacy and safety of azilsartan medoxomil combined with chlorthalidone in participants with moderate to severe hypertension (Factorial Study)

Common questions about Edarbyclor (FAQ)

Q: How is Edarbyclor different from just taking Azilsartan or Chlorthalidone alone?

Edarbyclor is a fixed-dose combination that includes two different types of blood pressure medicines. Clinical studies generally indicated that the combination was associated with greater reductions in systolic and diastolic blood pressure compared to using the individual components (monotherapy) alone. The combination is designed to target blood pressure control through two distinct mechanisms of action.

Q: How long does it usually take to see results after starting Edarbyclor?

Official dosing guidelines indicate that healthcare providers typically adjust the dose, if necessary, after two to four weeks of use based on blood pressure response. This timeframe is used by healthcare providers to assess the patient's blood pressure response and determine if a dose adjustment is necessary.

Q: Can Edarbyclor affect my potassium levels?

Yes, official labeling notes that Edarbyclor has the potential to affect potassium levels. Due to the diuretic component, the medication may lead to hypokalemia (low potassium), which is why periodic monitoring is a standard safety measure. The drug can also cause hyperkalemia (high potassium) when taken with certain other drugs, supplements, or salt substitutes.

Q: Does Edarbyclor have a risk of causing low blood pressure (hypotension)?

Yes, official safety information lists symptomatic hypotension (low blood pressure), which may lead to fainting, as a documented risk. This reaction is considered more likely to occur when treatment is first started, particularly in individuals who have volume or salt depletion.

Q: Can Edarbyclor affect my sleep?

Official adverse reaction lists indicate that fatigue is one of the most commonly reported side effects. Specific sleep disturbances, such as insomnia, are not explicitly listed among the common adverse reactions reported in clinical trials.

Q: Is it possible to have an allergic reaction to Edarbyclor?

Yes, the medication is officially contraindicated (must not be used) if there is a known hypersensitivity to any of the medication's components or to sulfonamide-derived drugs. Swelling, known as angioedema, which can affect the face, lips, or tongue, is a potential serious adverse reaction that has been reported.

Q: Does Edarbyclor require any special monitoring by a healthcare provider?

Yes, regulatory documents recommend specific monitoring due to the components in the medicine. Standard safety measures include periodic checks of serum electrolytes (like potassium and sodium) and monitoring of blood creatinine levels to assess kidney function.

Q: Does Edarbyclor treat any conditions other than high blood pressure?

The official indication for Edarbyclor is limited to the treatment of hypertension (high blood pressure). The regulatory documents do not mention its formal use for any other medical conditions.

Q: Can Edarbyclor cause a cough like some other blood pressure medicines?

Official adverse reaction reports include cough in the list of events observed in clinical trials. It is important to note that cough is not listed among the most commonly reported side effects for Edarbyclor.

Q: Is it normal to feel dizzy or lightheaded when taking Edarbyclor?

Dizziness is listed in regulatory documents as one of the most commonly reported adverse reactions reported by patients. The feeling of lightheadedness can also be related to a drop in blood pressure, which is a documented risk of the medication.

Q: Are there any major diet restrictions when taking Edarbyclor?

Official safety documents do not list general diet restrictions, but they do include warnings about products that may affect salt and potassium balance. Specifically, care should be taken regarding the use of potassium supplements and salt substitutes that contain potassium, as co-use may increase potassium levels.

Q: Is weight gain a possible side effect of Edarbyclor?

While weight gain is not listed as a common side effect in its own right, official warnings state that signs of worsening kidney function can include unexplained weight gain or swelling. This is a documented sign that is part of the overall safety monitoring related to kidney function.

Q: Does Edarbyclor contain sulfa, and is that a concern for people with a sulfa allergy?

Yes, the chlorthalidone component of the drug is classified as a sulfonamide-derived medicine. Because of this, the medication is officially contraindicated (must not be used) in patients who have a known history of allergy or hypersensitivity to sulfonamide-derived drugs.

Q: Is there a generic version of Edarbyclor available?

Yes, the fixed-dose combination of the active ingredients, azilsartan medoxomil and chlorthalidone, is available in approved generic versions for its various strengths.

Q: Why is Edarbyclor sometimes prescribed over other blood pressure drugs?

The drug is indicated for patients whose blood pressure is not adequately controlled with a single medicine (monotherapy), or as an initial treatment when a patient is expected to require multiple drugs. Clinical studies have generally indicated that this combination product is associated with greater blood pressure reductions compared to its individual components and some other dual-drug regimens.

Q: Can Edarbyclor change the results of certain lab tests?

Yes, official labeling notes that Edarbyclor may affect standard laboratory values. Potential changes include elevations in blood creatinine and blood urea nitrogen (BUN), and fluctuations in electrolytes such as potassium, sodium, and uric acid.

Q: What is the risk of swelling (angioedema) with Edarbyclor?

Angioedema is a serious type of swelling, typically affecting the face, lips, or tongue. This reaction has been reported in postmarketing surveillance and is a known potential risk associated with the drug's class (ARB medications).

Q: Does Edarbyclor affect blood sugar levels?

Official information mentions that thiazide-like diuretics, such as the chlorthalidone component, may be associated with changes in carbohydrate metabolism. Additionally, the medication is specifically contraindicated for use with Aliskiren in patients diagnosed with diabetes.

Q: What is the difference between Edarbyclor and other ARBs (Angiotensin II Receptor Blockers)?

Edarbyclor is specifically formulated as a fixed-dose combination that pairs an ARB (azilsartan medoxomil) with a diuretic (chlorthalidone). The use of the specific ARB component, azilsartan, in this dual therapy is supported by clinical data that indicated greater blood pressure reductions compared to a similar combination with a different ARB.

Q: Can Edarbyclor cause muscle cramps or spasms?

Yes, muscle spasm is an adverse reaction listed in the official prescribing information. Additionally, the chlorthalidone component can cause changes in electrolytes that may result in symptoms like muscle pains or cramps.

Q: Does Edarbyclor cause dehydration?

The diuretic component increases the excretion of fluid and sodium by the kidneys, which can potentially lead to volume and/or salt depletion. The safety information notes that symptoms of fluid imbalance, such as dry mouth or increased thirst, should be reported to a healthcare provider.

Q: How does the chlorthalidone component of Edarbyclor work?

Chlorthalidone is a thiazide-like diuretic that works directly on the kidneys. Its mechanism is to increase the excretion of sodium and water in the urine, which helps to reduce the volume of fluid in the bloodstream and contributes to the overall blood pressure lowering effect.

Q: What is the half-life of Edarbyclor?

The half-life refers to the time it takes for the drug concentration to decrease by half in the body. Official pharmacological data states that the elimination half-life of the azilsartan component is approximately 11 hours.

Q: Does Edarbyclor prevent heart attacks?

The drug's primary function is to lower high blood pressure. Regulatory information states that lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, including stroke and heart attack (myocardial infarction).

Q: Can Edarbyclor affect cholesterol levels?

Yes, diuretics like the chlorthalidone component have been associated with elevations in cholesterol and uric acid in clinical studies. For this reason, patients with pre-existing high lipid levels are among those for whom closer monitoring may be used in clinical practice.

How to Store and Dispose of Edarbyclor

Edarbyclor must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). The product is moisture sensitive and must be protected from both light and moisture to maintain stability.

Storage Requirements

Disposal

Dispose of any unused or expired Edarbyclor by following the current disposal guidelines provided by the U.S. Food and Drug Administration.